Helix Acquisition CORP Ii 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
BridgeBio Oncology Therapeutics reported Q2 2026 financial results, highlighting advancements in its clinical programs for RAS-pathway malignancies and a cash runway extending into 2028.
BridgeBio Oncology Therapeutics reports Q1 2026 financial results, highlights progress in three RAS-pathway inhibitor programs, and anticipates clinical readouts in H2 2026 with cash runway into 2028.
BridgeBio Oncology Therapeutics, Inc. announced the appointment of Peter Lebowitz, M.D., Ph.D. to its Board of Directors, expanding the board to nine members.
BridgeBio Oncology Therapeutics announced its full year 2025 financial results and positive clinical data across its three RAS-pathway inhibitor programs, extending its cash runway into 2028.
BridgeBio Oncology Therapeutics announced positive preliminary safety and antitumor data across three innovative RAS and PI3Ka pipeline programs.
BridgeBio Oncology Therapeutics, Inc. announced its third-quarter 2025 financial results, highlighting pipeline progress and a strong cash position extending into 2028.
BridgeBio Oncology Therapeutics, Inc. (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, debuting on the Nasdaq Global Market with approximately $382 million in gross proceeds.
Helix Acquisition Corp. II successfully retained over 60% of its trust account funds and secured a significant PIPE financing, paving the way for its business combination with BridgeBio Oncology Therapeutics.
Helix Acquisition Corp. II shareholders overwhelmingly approved all proposals, including the business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), paving the way for the company to be renamed BridgeBio Oncology Therapeutics, Inc.
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that their Registration Statement on Form S-4 for their proposed business combination has been declared effective by the SEC, paving the way for a shareholder vote and anticipated August 2025 closing.
Helix Acquisition Corp. II will merge with TheRas, Inc., a clinical-stage biopharmaceutical company, to advance novel small molecule therapeutics targeting RAS and PI3K a malignancies.
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a definitive business combination agreement to create a publicly listed biotechnology company focused on advancing a pipeline of RAS and PI3K-targeting medicines.
Helix Acquisition Corp. II appoints Albert A. Holman, III to its board of directors, enhancing its expertise in the life science industry.
Helix Acquisition Corp. II reports its audited balance sheet as of February 13, 2024, following the completion of its $184 million initial public offering.
Helix Acquisition Corp. II successfully closed its upsized initial public offering, raising $184 million, including the full exercise of the underwriters' over-allotment option.